US20220333093A1 - Site-specific conjugation to antibody lysine residues with solid-phase immobilized microbial transglutaminase mtg and mtg in solution - Google Patents
Site-specific conjugation to antibody lysine residues with solid-phase immobilized microbial transglutaminase mtg and mtg in solution Download PDFInfo
- Publication number
- US20220333093A1 US20220333093A1 US17/704,960 US202217704960A US2022333093A1 US 20220333093 A1 US20220333093 A1 US 20220333093A1 US 202217704960 A US202217704960 A US 202217704960A US 2022333093 A1 US2022333093 A1 US 2022333093A1
- Authority
- US
- United States
- Prior art keywords
- mtg
- antibody
- conjugation
- poly
- site
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000021615 conjugation Effects 0.000 title claims abstract description 64
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 title claims abstract description 15
- 108060008539 Transglutaminase Proteins 0.000 title claims abstract description 7
- 230000000813 microbial effect Effects 0.000 title claims abstract description 7
- 102000003601 transglutaminase Human genes 0.000 title claims abstract description 7
- 239000007790 solid phase Substances 0.000 title abstract description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 50
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 18
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract description 15
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000004472 Lysine Substances 0.000 claims abstract description 12
- 230000000694 effects Effects 0.000 claims abstract description 11
- 229920000642 polymer Polymers 0.000 claims description 48
- -1 p-aminobenzyloxycarbonyl Chemical group 0.000 claims description 40
- 239000000243 solution Substances 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 36
- 239000011325 microbead Substances 0.000 claims description 22
- 239000012634 fragment Substances 0.000 claims description 14
- 239000012530 fluid Substances 0.000 claims description 10
- 239000011521 glass Substances 0.000 claims description 10
- 125000006850 spacer group Chemical group 0.000 claims description 10
- 229920001223 polyethylene glycol Polymers 0.000 claims description 8
- 229920002307 Dextran Polymers 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000002738 chelating agent Substances 0.000 claims description 6
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 230000035772 mutation Effects 0.000 claims description 6
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 150000001540 azides Chemical class 0.000 claims description 5
- 239000007850 fluorescent dye Substances 0.000 claims description 5
- 150000002484 inorganic compounds Chemical class 0.000 claims description 5
- 229910010272 inorganic material Inorganic materials 0.000 claims description 5
- URYYVOIYTNXXBN-OWOJBTEDSA-N trans-cyclooctene Chemical group C1CCC\C=C\CC1 URYYVOIYTNXXBN-OWOJBTEDSA-N 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- 238000012650 click reaction Methods 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 229910021389 graphene Inorganic materials 0.000 claims description 4
- 229920000773 poly(2-methyl-2-oxazoline) polymer Polymers 0.000 claims description 4
- 229920001610 polycaprolactone Polymers 0.000 claims description 4
- 239000004632 polycaprolactone Substances 0.000 claims description 4
- 229920000139 polyethylene terephthalate Polymers 0.000 claims description 4
- 239000005020 polyethylene terephthalate Substances 0.000 claims description 4
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 4
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 claims description 4
- 229920000936 Agarose Polymers 0.000 claims description 3
- 239000004793 Polystyrene Substances 0.000 claims description 3
- 239000012062 aqueous buffer Substances 0.000 claims description 3
- 230000001588 bifunctional effect Effects 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 230000001268 conjugating effect Effects 0.000 claims description 3
- 229920000736 dendritic polymer Polymers 0.000 claims description 3
- 150000004676 glycans Chemical class 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 229920001282 polysaccharide Polymers 0.000 claims description 3
- 239000005017 polysaccharide Substances 0.000 claims description 3
- 229920002223 polystyrene Polymers 0.000 claims description 3
- 150000004905 tetrazines Chemical class 0.000 claims description 3
- 239000003053 toxin Substances 0.000 claims description 3
- 231100000765 toxin Toxicity 0.000 claims description 3
- OGBQILNBLMPPDP-UHFFFAOYSA-N 2,3,4,7,8-Pentachlorodibenzofuran Chemical compound O1C2=C(Cl)C(Cl)=C(Cl)C=C2C2=C1C=C(Cl)C(Cl)=C2 OGBQILNBLMPPDP-UHFFFAOYSA-N 0.000 claims description 2
- OUCMTIKCFRCBHK-UHFFFAOYSA-N 3,3-dibenzylcyclooctyne Chemical compound C1CCCCC#CC1(CC=1C=CC=CC=1)CC1=CC=CC=C1 OUCMTIKCFRCBHK-UHFFFAOYSA-N 0.000 claims description 2
- GOUHYARYYWKXHS-UHFFFAOYSA-M 4-formylbenzoate Chemical compound [O-]C(=O)C1=CC=C(C=O)C=C1 GOUHYARYYWKXHS-UHFFFAOYSA-M 0.000 claims description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 2
- 229920002101 Chitin Polymers 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 101000945318 Homo sapiens Calponin-1 Proteins 0.000 claims description 2
- 101000652736 Homo sapiens Transgelin Proteins 0.000 claims description 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 2
- 239000000020 Nitrocellulose Substances 0.000 claims description 2
- 239000004677 Nylon Substances 0.000 claims description 2
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 229920002845 Poly(methacrylic acid) Polymers 0.000 claims description 2
- 229920002319 Poly(methyl acrylate) Polymers 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims description 2
- 229920002873 Polyethylenimine Polymers 0.000 claims description 2
- 108010020346 Polyglutamic Acid Proteins 0.000 claims description 2
- 108010039918 Polylysine Proteins 0.000 claims description 2
- 239000004743 Polypropylene Substances 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 229920000297 Rayon Polymers 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 235000006732 Torreya nucifera Nutrition 0.000 claims description 2
- 244000111306 Torreya nucifera Species 0.000 claims description 2
- 239000007983 Tris buffer Substances 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 150000001299 aldehydes Chemical class 0.000 claims description 2
- 229940072056 alginate Drugs 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 150000001345 alkine derivatives Chemical class 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 2
- 150000001735 carboxylic acids Chemical class 0.000 claims description 2
- 239000000679 carrageenan Substances 0.000 claims description 2
- 229920001525 carrageenan Polymers 0.000 claims description 2
- 235000010418 carrageenan Nutrition 0.000 claims description 2
- 229940113118 carrageenan Drugs 0.000 claims description 2
- 229920002301 cellulose acetate Polymers 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 150000001939 cyclooctenes Chemical class 0.000 claims description 2
- ZPWOOKQUDFIEIX-UHFFFAOYSA-N cyclooctyne Chemical group C1CCCC#CCC1 ZPWOOKQUDFIEIX-UHFFFAOYSA-N 0.000 claims description 2
- 150000001943 cyclopropenes Chemical class 0.000 claims description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 2
- 150000002118 epoxides Chemical class 0.000 claims description 2
- 229920000840 ethylene tetrafluoroethylene copolymer Polymers 0.000 claims description 2
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 230000002068 genetic effect Effects 0.000 claims description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052737 gold Inorganic materials 0.000 claims description 2
- 239000010931 gold Substances 0.000 claims description 2
- 150000002429 hydrazines Chemical class 0.000 claims description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 2
- 150000002466 imines Chemical class 0.000 claims description 2
- 230000002519 immonomodulatory effect Effects 0.000 claims description 2
- 210000002865 immune cell Anatomy 0.000 claims description 2
- 150000002540 isothiocyanates Chemical class 0.000 claims description 2
- 229910044991 metal oxide Inorganic materials 0.000 claims description 2
- 150000004706 metal oxides Chemical class 0.000 claims description 2
- 229940063557 methacrylate Drugs 0.000 claims description 2
- ZZBSAWJCURVBAK-UHFFFAOYSA-N n-(2,5-dioxopyrrolidin-1-yl)-6-hydrazinylpyridine-3-carboxamide Chemical compound C1=NC(NN)=CC=C1C(=O)NN1C(=O)CCC1=O ZZBSAWJCURVBAK-UHFFFAOYSA-N 0.000 claims description 2
- QNILTEGFHQSKFF-UHFFFAOYSA-N n-propan-2-ylprop-2-enamide Chemical compound CC(C)NC(=O)C=C QNILTEGFHQSKFF-UHFFFAOYSA-N 0.000 claims description 2
- 229910052759 nickel Inorganic materials 0.000 claims description 2
- 150000002825 nitriles Chemical class 0.000 claims description 2
- 229920001220 nitrocellulos Polymers 0.000 claims description 2
- 229920001778 nylon Polymers 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 2
- 229920002454 poly(glycidyl methacrylate) polymer Polymers 0.000 claims description 2
- 229920002401 polyacrylamide Polymers 0.000 claims description 2
- 229920000058 polyacrylate Polymers 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- 229920000656 polylysine Polymers 0.000 claims description 2
- 229920006324 polyoxymethylene Polymers 0.000 claims description 2
- 229920001155 polypropylene Polymers 0.000 claims description 2
- 229920001451 polypropylene glycol Polymers 0.000 claims description 2
- 229920001296 polysiloxane Polymers 0.000 claims description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 239000002964 rayon Substances 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 229920001059 synthetic polymer Polymers 0.000 claims description 2
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 claims description 2
- 150000003573 thiols Chemical class 0.000 claims description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims 9
- 102000036639 antigens Human genes 0.000 claims 9
- 108091007433 antigens Proteins 0.000 claims 9
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 102100031013 Transgelin Human genes 0.000 claims 1
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 claims 1
- 125000003827 glycol group Chemical group 0.000 claims 1
- 125000004404 heteroalkyl group Chemical group 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 230000000717 retained effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 abstract description 36
- 108090000623 proteins and genes Proteins 0.000 abstract description 36
- 102000004190 Enzymes Human genes 0.000 abstract description 18
- 108090000790 Enzymes Proteins 0.000 abstract description 18
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 14
- 230000009977 dual effect Effects 0.000 abstract description 8
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 abstract description 7
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 abstract description 7
- 230000002459 sustained effect Effects 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 230000000740 bleeding effect Effects 0.000 abstract description 2
- 239000012071 phase Substances 0.000 abstract description 2
- 230000004962 physiological condition Effects 0.000 abstract description 2
- 230000003389 potentiating effect Effects 0.000 abstract description 2
- 230000009145 protein modification Effects 0.000 abstract 2
- 238000004064 recycling Methods 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 26
- 235000004554 glutamine Nutrition 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 12
- 239000000758 substrate Substances 0.000 description 9
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 6
- 108090001008 Avidin Proteins 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 108010093096 Immobilized Enzymes Proteins 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
- CCSGGWGTGOLEHK-OBJOEFQTSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(5-aminopentyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCN)SC[C@@H]21 CCSGGWGTGOLEHK-OBJOEFQTSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 150000003141 primary amines Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000007306 functionalization reaction Methods 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- 108091007914 CDKs Proteins 0.000 description 1
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 description 1
- 102100033620 Calponin-1 Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
- PGJBQBDNXAZHBP-UHFFFAOYSA-N Dimefox Chemical compound CN(C)P(F)(=O)N(C)C PGJBQBDNXAZHBP-UHFFFAOYSA-N 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091006012 Myc-tagged proteins Proteins 0.000 description 1
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 description 1
- OAAQPYUFAOHUMT-UHFFFAOYSA-N N-butyl-N-(3-carboxypropyl)nitrosamine Chemical compound CCCCN(N=O)CCCC(O)=O OAAQPYUFAOHUMT-UHFFFAOYSA-N 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241001495137 Streptomyces mobaraensis Species 0.000 description 1
- DPOPAJRDYZGTIR-UHFFFAOYSA-N Tetrazine Chemical compound C1=CN=NN=N1 DPOPAJRDYZGTIR-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- HQMRIBYCTLBDAK-UHFFFAOYSA-M bis(2-methylpropyl)alumanylium;chloride Chemical compound CC(C)C[Al](Cl)CC(C)C HQMRIBYCTLBDAK-UHFFFAOYSA-M 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000006352 cycloaddition reaction Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 150000002309 glutamines Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000002514 liquid chromatography mass spectrum Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- MLEBFEHOJICQQS-UHFFFAOYSA-N monodansylcadaverine Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(=O)(=O)NCCCCCN MLEBFEHOJICQQS-UHFFFAOYSA-N 0.000 description 1
- RMTLMTYIGIOBQR-UHFFFAOYSA-N n-(2,5-dioxopyrrolidin-1-yl)-4-formylbenzamide Chemical compound C1=CC(C=O)=CC=C1C(=O)NN1C(=O)CCC1=O RMTLMTYIGIOBQR-UHFFFAOYSA-N 0.000 description 1
- GASFVSRUEBGMDI-UHFFFAOYSA-N n-aminohydroxylamine Chemical compound NNO GASFVSRUEBGMDI-UHFFFAOYSA-N 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000012510 peptide mapping method Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 239000012508 resin bead Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
- C12N11/089—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6887—Antibody-chelate conjugates using chelates for therapeutic purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
- A61K47/6937—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/104—Aminoacyltransferases (2.3.2)
- C12N9/1044—Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y203/00—Acyltransferases (2.3)
- C12Y203/02—Aminoacyltransferases (2.3.2)
- C12Y203/02013—Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
Definitions
- the present invention relates to a method for the conjugation of organic molecules to proteins and the creation of fusion proteins using microbead-immobilized MTG (microbial transglutaminase MTG) and/or MTG polymer conjugate in solution and/or free MTG in solution.
- microbead-immobilized MTG microbial transglutaminase MTG
- MTG polymer conjugate in solution and/or free MTG in solution.
- Bio-conjugation reactions performed by enzymes typically show rapid kinetics at low reagent concentrations (submillimolar), a high conversion efficiency and it can be done under physiological conditions.
- Policarpo et al. showed most recently the conjugation of an enzyme onto Ni-NTA agarose beads. Unfortunately, this conjugation has a non-covalent nature and shows a high risk to column-bleeding.
- This objective is achieved according to the present invention by a method for the conjugation of organic molecules to target proteins and the creation of fusion proteins using an immobilized and/or non-immobilized form of MTG (microbial transglutaminase), comprising the steps of:
- This method offers for the first time the opportunity to conjugate organic molecules to proteins with a high conversion of the educts in order to form efficiently the protein organic molecule conjugate. Due to the covalent binding of the MTG to the polymer, bleeding of MTG can be suppressed to an advantageous degree.
- This method surprisingly leads by the immobilization of the enzyme to an enhanced selectivity towards one (or more desired) enzyme-reactive residue on the protein, peptide or other biomolecule to be conjugated in the presence of multiple reactive residues which would be all targeted if the conjugation was done with non-immobilized enzyme in solution. This would lead to an undesired mixture of molecules conjugated to different extents or a complete conjugation of all residues.
- MTG is preferably from the organism streptomyces mobaraensis.
- the binding of the polymer to the microbeads can be achieved in a stable manner when the polymer undergoes an ionic and/or a covalent binding to the microbeads.
- Preferred example for the polymer can be a second generation dendronized polymer (de-PG2).
- the target protein can be selected from a group consisting of: an antibody of IgG, IgM, IgA or IgE format or a fragment thereof and is preferably monoclonal which optionally selected to be chimeric, humanized or bispecific, deglycosylated or non-glycosylated containing a N297 mutation (e.g. N297Q or N297A) (EU numbering scheme), and preferably also comprise other reactive glutamine residue mutations in the antibody backbone that enable MTG-mediated conjugation.
- a N297 mutation e.g. N297Q or N297A
- the target protein is a peptide, such as Fab, Fab′, F(ab)′2, F(ab)′3, Dab, Fv, single chain Fv (scFv) fragment scFv-Fc (scFv) 2 wherein further possible proteins and/or peptides include proteins and peptide involved in recognition of other proteins and peptides, including, but are not limited to protein kinases such as mitogen activated protein (MAP) kinase, and kinases that directly or indirectly phosphorylate MAP kinase, Januse kinase (JAKI) and cyclin dependent kinases, epidermal growth factor (EGF) receptor, platelet-derived growth factor (PDGF) receptor, fibroblast-derived growth factor (FGF) receptor, insulin receptor and insulin-like growth factor (IGF), engineered proteins like darpins, affibody/nanobodies or fibronectin fragments, or carrier proteins or
- MAP mitogen activated protein
- the enzyme may modify either one or more reactive glutamine residue (e.g. Q295 and N297Q in antibodies) or one or more reactive lysine residue on the target protein (e.g. K288 or K290, K340 in antibodies) with an organic molecule; wherein the residue is endogenously or artificially introduced by genetic means or a combination thereof.
- reactive glutamine residue e.g. Q295 and N297Q in antibodies
- reactive lysine residue on the target protein e.g. K288 or K290, K340 in antibodies
- Preferred embodiments for the organic molecule to be conjugated to the target protein can be selected from a group consisting of: a fluorescent dye/label (e.g. Alexa488, Alexa 647), a cell-cytotoxic or influencing moiety, such as toxins or cell regulators, immune cell immunomodulatory/stimulating compounds, a metal-chelator (e.g. NODA-GA) suitable for SPECT/PET or MRI, a functional peptide (e.g.
- alpha defensin NP-1 alpha defensin NP-1
- a chemical moiety suitable for click-reactions like strain-promoted azide-alkyne click chemistry (SPAAC) or tetrazine-alkene ligation including azides and cyclooctyne derivatives (e.g. DIFO, BCN, DIBAC, DIBO, ADIBO), and tetrazines and trans-cyclooctenes derivatives with a primary amine for MTG-mediated conjugation and a spacer moiety with C n >20.
- SPAAC strain-promoted azide-alkyne click chemistry
- tetrazine-alkene ligation including azides and cyclooctyne derivatives (e.g. DIFO, BCN, DIBAC, DIBO, ADIBO), and tetrazines and trans-cyclooctenes derivatives with a primary amine for MTG-mediated conjug
- the organic molecule may be selected from a group consisting of: peptides with (C+N) n >20 conjugated to a functional moiety like a cytotoxic moiety, fluorescent dye, metal chelator, or a chemical moiety that is suitable for SPAAC click-reaction (e.g. azide or DBCO-groups) or a tetrazine and trans-cyclooctene group or derivatives thereof.
- the peptides may comprise a lysine (e.g. KNAA or KAYA) or a glutamine residue (e.g. FGLQPRY) and which is targeted by MTG (i.e. a substrate for MTG), optionally it comprises a spacer moiety of C n >20 (e.g. poly-ethylene glycol, alkyl group) and/or is conjugated via a primary amine.
- the organic molecule can be selected from a group consisting of: peptides comprising a lysine at any position (e.g. KNAAGGG or KDAAGGG or KAYAGGG or AKETAA) or a glutamine residue at any position (e.g. FGLQPRY, SLLQGR) and which is targeted by MTG (i.e. a substrate for MTG), and which optionally contains an enzymatically cleavable peptidic sequence (e.g.
- valine-citrulline VC
- KNAAGGG-VC valine-citrulline
- said lysine peptide has a size (length) of (C+N) n >20 and said glutamine peptide has a size (length) of 1 ⁇ (C+N) n ⁇ 200.
- Preferred embodiments for the microbeads or microbead resin can be selected from a group consisting of: glass, nickel, polyethylene, polypropylene, poly(4-methulbutene), polystyrene, polyacrylate, polyethylene terephthalate, rayon, nylon, poly(vinyl butyrate), polyvinylidene difluoride (PCDF), silicones, polyformaldehyde, cellulose, cellulose acetate, nitrocellulose, and the like.
- solid supports include gelatin, glass, sepharose macrobeads, sephadex beads or dextran microcarriers such as CYTODES® (Pharmacia, Uppsala, Sweden), polysaccharide such as agarose, alginate, carrageenan, chitin, cellulose, dextran or starch, polycaprolactone (PCL), polyacrylamide, polystyrene, polyacrolein, polydimethylsiloxane, polyvinyl alcohol, polymethylacrylate, perfluorocarbon, inorganic compounds such as silica, glass, kieselguhr, alumina, gold, iron oxide, graphene & graphene oxide or other metal oxides, or copolymers consisting of any combination of two or more naturally occurring polymers, synthetic polymers or inorganic compounds.
- the bead size can vary from 1 to 100 nm or from 100 to 1000 nm or from 1 ⁇ m to 10 ⁇ m or from 10 ⁇ m to 1000 ⁇
- Suitable examples for the fluid can be selected from a group consisting of: water containing suitable buffer (e.g. Tris) and salt additives (e.g. NaCl), said aqueous buffer solutions also may contain glycerol and other organic solvents like ethanol, propanol, isopropanol, 1-propanol, DMSO, methanol, acetonitrile up to 60%.
- suitable buffer e.g. Tris
- salt additives e.g. NaCl
- glycerol and other organic solvents like ethanol, propanol, isopropanol, 1-propanol, DMSO, methanol, acetonitrile up to 60%.
- suitable polymers can be selected from a group consisting of:
- polyNIPAM poly-N-isopropylacrylamide
- PTFE polytetrafluoroethylene
- ETFE poly(ethylene-alt-tetrafluoroethylene)
- POEGMA poly(2-methyl-2-oxazoline)
- PMOXA poly(vinyl alcohol)
- PVA poly(ethylene imine) and derivatives thereof.
- the conjugation of the MTG and the polymer involves a linker (spacer) among the polymer and the MTG, said linker can be selected from a group consisting of:
- bifunctional linker system S-HyNic (succinimidyl-6-hydrazino-nicotinamide, S-4FB (4-formylbenzoate) or derivatives thereof, or SMCC (succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate) or derivatives thereof, homo- or heterobifunctional spacers which have a structure like Y-S-Z (Y can also be Z and vice versa), whereas Y and Z are of the following group or derivatives thereof: tetrazines, trans-cyclooctenes, azides, cyclooctenes (e.g.
- n-hydroxysuccinimide maleimide, isothiocyanate, aldehyde, epoxides, alcohols, amines, thiols, phosphonates, alkynes, potassium acyltrifluoroborates, a-ketoacid-hydroxylamines, O-acylhydroxylamines, carboxylic acids, hydrazines, imines, norborenes, nitriles and cyclopropenes, and S is a spacer entity being a polymer or derivatives thereof, e.g. oligo or poly(ethylene glycol) (PEG), dextranes, made of an alkylmoieties, amino acids or peptide derivatives
- Suitable conditions for the conjugation proceed can be achieved when the determined conditions comprise the following details: a temperature range between 0° C. and 50° C., contact time of a few seconds to 168 h (or 7 d), a flow-speed/velocity of smaller than 1 ⁇ L/min or 1 ⁇ L/min-10 ml/min in the active flow reactor column, protein concentrations of 1 ⁇ M to 1 mM with an organic molecule molar ratio to the target protein of 0.5 to 50x or 50 to 500x or 500 to 10′000x and with a MTG concentration of 0.001 mg/ml to 0.01 mg/ml or 0.01 mg/ml to 10 mg/ml per ml of resin or microbeads or of the conjugation solution, further preferably also including a conjugation efficiency to the target protein with the organic molecule of at least 30% and up to 100% conversion and a flow-pressure of 0.1 bar to 20 bar.
- the functionalized microbeads can also be placed in a spin-column suitable device, where the reaction mixture is incubated with the microbeads for a certain amount of time from 1 s to 60 s, 1 min to 60 min, 1 h to 168 h. The mixture is then removed from the microbeads again by centrifugation and taking away the supernatant or the solution is pushed through a suitable filter device during centrifugation retaining the microbeads but not the reaction desired mixture/conjugate.
- FIG. 1 schematically the microbial transglutaminase MTG immobilization process on de-PG2 polymer and subsequent adsorption on microbeads;
- FIGS. 2A-2D characteristics and quantification of the conjugation of the MTG on the de-PG2 polymer and MTG, MTG-polymer conjugate activity normalized to 1 ⁇ M MTG;
- FIGS. 3A-3C schematically the conjugation of functional molecules to antibody-like scaffolds like scFV and Fab-Fragment using microbead-immobilized MTG;
- FIGS. 4A-4C schematically the conjugation of functional molecules to (non-glycosylated) antibodies (N297S or N297Q mutants) using microbead-immobilized MTG; and also MTG attached to the polymer detection by the anti-MTG antibody;
- FIG. 5 Immobilized MTG enhanced selectivity in the presence of several reactive amino acids compared to when the conjugation is done in solution;
- FIG. 6 Screening of glutamine containing peptides (sequence given in table on the right) to deglycosylated IgG1 (Herceptin) using different pH conditions. Peptide 2 was found to be most potent at pH 7.6 yielding ⁇ 50% conjugation;
- FIG. 7 Structure of peptide 2 (left) and its azide-derivative (right);
- FIG. 8 Conjugation of deglycosylated IgG1 with peptide FGLQRPY (peptide 2) using solid-phase immobilized MTG;
- FIG. 9 Conjugation of peptide 2 to IgG1 (contains a N297S mutation) with immobilized MTG (left) and with MTG in solution (right) yielding>70% conjugation;
- FIG. 10 Conjugation of peptide 2-azide derivative to lysine 340 and lysine 288/290 of IgG1 N297S antibody with immobilized MTG (left) and with MTG in solution (right) yielding>70% conjugation;
- FIG. 11 Dual site-specific conjugation using immobilized (left) and MTG in solution (right) to IgG1 N297S antibody yielding ⁇ 40% dual site-specifically modified IgG1.
- FIG. 12 SDS-PAGE coomassie and fluorescence analysis of lysine conjugated antibodies. Only heavy chains are selectively conjugated, no light chain.
- MTG-(4FB) 2 could lead to undesired over-crosslinking on the same or another polymer-strand, to a reduced MTG activity as well as to a decreased solubility of the enzyme-polymer conjugate. For these reasons particular emphasis was taken not to over-conjugate the MTG and chose an excess of 1.5 4FB to MTG generating>90% pure, single-linked MTG.
- the UV-VIS quantifiable bis-aryl-hydrazone bond at 354 nm allowed to estimate the bead-immobilized MTG amount from eluted volume. After 1 h incubation, the concentration was determined to 1.6 ⁇ 0.15 ⁇ M in the eluted volume and given the starting concentration of 5 ⁇ M, about 70% of the conjugate has adsorbed on the beads. Since the MTG is mostly single cross-linked to the polymer, we can estimate an adsorbed mass of ⁇ 300 ng/cm 2 or ⁇ 7.8 pmol MTG/cm 2 . These values agree to previously published results using proteinase K or horseradish-peroxidase immobilized on denpol-polymers and other enzymes, covalently immobilized on silica-polymer-surfaces.
- microbeads For the stable immobilization of the MTG-polymer conjugate glass microbeads were chosen to be used due to the strong affinity of the positively charged denpol-amines to negatively charged glass surfaces and since beads can easily be assembled into a flow-based microreactor. Such a set-up enables for a repeated sample bead-overflowing in a well-controllable manner and hence can be used to drive the reaction towards completion. Furthermore, the microbeads can simply be washed after the conjugation process recovering the immobilized MTG for the next round of conjugation.
- Therapeutic relevant proteins of smaller antibody-like scaffolds including scFV, nanobodies or Fab-fragments have been of considerable interest due to their increased tumor penetration capability, their facile production and more rapid clearance compared to larger antibodies.
- Dansylcadaverine a fluorescent amine donor for MTG, was also conjugated at an excess of just 8 equimolar to Fab and scFV ( FIG. 3 a ) which resulted in ⁇ 95% dansyl-labeled Fab-Fragment and ⁇ 90% scFV within 30 min ( FIG. 3 b ).
- Immobilized MTG was therefore subjected to an IgG1 antibody containing a N297S point mutation to obviate deglycosylation and biotin-cadaverine ( FIG. 4 a ).
- LC-MS analysis of reduced antibody already showed 37% heavy chain conversion and 72% after 1 h at room temperature, increasing to 95% during overnight incubation ( FIG. 4 a ).
- Site-specifically modified antibodies with high drug-to-antibody-ratio (DAR) of 4-6 are considered to effectively deliver the conjugated drugs to the tumor target site compared to conventionally, non-specifically conjugated antibodies having the same drug load making such ADCs very attractive as improved cancer therapeutics.
- DAR drug-to-antibody-ratio
- the polycationic nature of the denpol-polymer was previously shown to provide a stable surface-anchoring for several weeks on anionic glass surfaces. Since a solid enzyme immobilization is important for downstream applications particularly for prospective therapeutic proteins, one addressed enzyme-leaking using slot-blot assay and anti-MTG antibody. One chose slot-blot as it allows application of large sample volumes and due to its sensitivity.
- MTG-polymer conjugate as a positive control showed a strong signal ( FIG. 4 c , lane 1 I), also unconjugated MTG could be detected (lane 1 , ii) while HyNic-polymer did not produce a signal (lane 1 iii) demonstrating that the antibody specifically recognized the MTG, also when conjugated to the polymer.
- the solubility of the functional moiety (“the payload”) could be increased which is very beneficial for hydrophobic payloads.
- the payload could be conjugated with high efficiency (>95%) as well as KNAA-GK-PEG3-NODAGA and KAYA-GK-PEG3-NODAGA to deglycosylated antibody.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Nanotechnology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Site-specific modification of proteins with microbial transglutaminase (MTG) is a powerful and versatile strategy for a controlled modification of proteins under physiological conditions. We present evidence that solid-phase microbead-immobilization can be used to site-specifically and efficiently attach different functional molecules important for further downstream applications to proteins of therapeutic relevance including scFV, Fab-fragment and antibodies. We demonstrate that MTG remained firmly immobilized with no detectable column bleeding and that enzyme activity was sustained during continuous operation, which allowed for a convenient recycling of the enzyme, thus going beyond solution-phase MTG conjugation. In addition it is showed that immobilized MTG shows enhanced selectivity towards a certain residue in the presence of several reactive residues which are all targeted if the conjugation was carried out in solution. It is also reported on the site-specific lysine conjugation of antibodies using potent glutamine containing peptides with immobilized and MTG in solution. In addition, the generation of dual site-specifically conjugated IgG1 with immobilized and MTG in solution is reported, i.e. site-specific conjugation to glutamine and lysine residues of IgG1 antibody. Site-specific glutamine conjugation with small peptides containing a lysine residue and a functional moiety is also described.
Description
- This application is a continuation of U.S. patent application Ser. No. 16/319,502, filed Jan. 22, 2019, which is a 35 U.S.C. § 371 filing of International Patent Application No. PCT/EP2017/067403, filed Jul. 11, 2017, which claims priority to European Patent Application No. 16180382.0, filed Jul. 20, 2016, the entire contents of which are hereby incorporated herein by reference.
- The present invention relates to a method for the conjugation of organic molecules to proteins and the creation of fusion proteins using microbead-immobilized MTG (microbial transglutaminase MTG) and/or MTG polymer conjugate in solution and/or free MTG in solution.
- In recent years, enzymatic site-specific functionalization of proteins has gained considerable interest in the bio-conjugation field. Bio-conjugation reactions performed by enzymes typically show rapid kinetics at low reagent concentrations (submillimolar), a high conversion efficiency and it can be done under physiological conditions.
- Despite these benefits, the enzymes have subsequently to be removed from the mixture to avoid any downstream interference and thus get lost. Through solid-phase immobilization this could be circumvented with a simple recovery of the enzyme. Immobilization of enzymes has so far almost exclusively been applied for the conversion of small compounds and was reported to enhance enzyme stability and also to lead to an increased activity, selectivity or selectivity. Tunable properties (i.e. enhanced selectivity towards certain residues) of immobilized enzymes for the site-specific modification of large molecular weight substrates like proteins under continuous operation for several rounds of conjugation of different protein formats has not been reported yet.
- Policarpo et al. showed most recently the conjugation of an enzyme onto Ni-NTA agarose beads. Unfortunately, this conjugation has a non-covalent nature and shows a high risk to column-bleeding.
- It is therefore the objective of the present invention to provide a method that provides a firmly immobilized enzyme for use in an active flow reactor column or in spin columns achieving a high rate and/or an enzyme in solution for the desired conjugation of an organic molecule to a protein while avoiding significantly any column-bleeding of the enzyme.
- This objective is achieved according to the present invention by a method for the conjugation of organic molecules to target proteins and the creation of fusion proteins using an immobilized and/or non-immobilized form of MTG (microbial transglutaminase), comprising the steps of:
- a) attaching the MTG to a polymer by exposing a cross-reactive group of said polymer for the immobilization of the MTG;
- b) adsorbing the MTG polymer conjugate on microbeads or bringing the MTG polymer conjugate into a solution;
- c) filling an active flow reactor column with the MTG polymer conjugate adsorbed microbeads and/or with the solution comprising the MTG polymer conjugate and/or a solution comprising the MTG;
- d) providing the target protein and the organic molecule within a fluid and passing the fluid through the filled active flow reactor column or mixing the fluid with the solution comprising the MTG polymer conjugate and/or the solution comprising MTG under determined conditions, thereby conjugating the organic molecules to the protein under the catalyzing effect of the MTG;
- e) extracting the protein organic molecule conjugate from the fluid.
- This method offers for the first time the opportunity to conjugate organic molecules to proteins with a high conversion of the educts in order to form efficiently the protein organic molecule conjugate. Due to the covalent binding of the MTG to the polymer, bleeding of MTG can be suppressed to an advantageous degree. This method surprisingly leads by the immobilization of the enzyme to an enhanced selectivity towards one (or more desired) enzyme-reactive residue on the protein, peptide or other biomolecule to be conjugated in the presence of multiple reactive residues which would be all targeted if the conjugation was done with non-immobilized enzyme in solution. This would lead to an undesired mixture of molecules conjugated to different extents or a complete conjugation of all residues. Using thus an immobilized form of MTG, only one (or more desired) residue is targeted and conjugated, respectively. Of course, the MTG can be also used in its free form in solution and/or as an MTG polymer conjugate that is brought into a solution. With respect to MTG, a person skilled in the art understands that the MTG is preferably from the organism streptomyces mobaraensis.
- The binding of the polymer to the microbeads can be achieved in a stable manner when the polymer undergoes an ionic and/or a covalent binding to the microbeads. Preferred example for the polymer can be a second generation dendronized polymer (de-PG2).
- According to preferred embodiments of the present invention, the target protein can be selected from a group consisting of: an antibody of IgG, IgM, IgA or IgE format or a fragment thereof and is preferably monoclonal which optionally selected to be chimeric, humanized or bispecific, deglycosylated or non-glycosylated containing a N297 mutation (e.g. N297Q or N297A) (EU numbering scheme), and preferably also comprise other reactive glutamine residue mutations in the antibody backbone that enable MTG-mediated conjugation.
- According to another preferred embodiments of the present invention, the target protein is a peptide, such as Fab, Fab′, F(ab)′2, F(ab)′3, Dab, Fv, single chain Fv (scFv) fragment scFv-Fc (scFv)2 wherein further possible proteins and/or peptides include proteins and peptide involved in recognition of other proteins and peptides, including, but are not limited to protein kinases such as mitogen activated protein (MAP) kinase, and kinases that directly or indirectly phosphorylate MAP kinase, Januse kinase (JAKI) and cyclin dependent kinases, epidermal growth factor (EGF) receptor, platelet-derived growth factor (PDGF) receptor, fibroblast-derived growth factor (FGF) receptor, insulin receptor and insulin-like growth factor (IGF), engineered proteins like darpins, affibody/nanobodies or fibronectin fragments, or carrier proteins or haptens, eliciting an immune response and thus are important for vaccination such as CRM197, a mutant of diphtheria toxin, or GBS67 (ancillary protein of PI-2a); furthermore it preferably also includes the conjugation to non-protein structures like e.g. single or multimeric dextrans like glucan.
- With respect to the enzyme, the enzyme may modify either one or more reactive glutamine residue (e.g. Q295 and N297Q in antibodies) or one or more reactive lysine residue on the target protein (e.g. K288 or K290, K340 in antibodies) with an organic molecule; wherein the residue is endogenously or artificially introduced by genetic means or a combination thereof.
- Preferred embodiments for the organic molecule to be conjugated to the target protein can be selected from a group consisting of: a fluorescent dye/label (e.g. Alexa488, Alexa 647), a cell-cytotoxic or influencing moiety, such as toxins or cell regulators, immune cell immunomodulatory/stimulating compounds, a metal-chelator (e.g. NODA-GA) suitable for SPECT/PET or MRI, a functional peptide (e.g. alpha defensin NP-1), a chemical moiety suitable for click-reactions like strain-promoted azide-alkyne click chemistry (SPAAC) or tetrazine-alkene ligation including azides and cyclooctyne derivatives (e.g. DIFO, BCN, DIBAC, DIBO, ADIBO), and tetrazines and trans-cyclooctenes derivatives with a primary amine for MTG-mediated conjugation and a spacer moiety with Cn>20.
- Further, the organic molecule may be selected from a group consisting of: peptides with (C+N)n>20 conjugated to a functional moiety like a cytotoxic moiety, fluorescent dye, metal chelator, or a chemical moiety that is suitable for SPAAC click-reaction (e.g. azide or DBCO-groups) or a tetrazine and trans-cyclooctene group or derivatives thereof. In particular, the peptides may comprise a lysine (e.g. KNAA or KAYA) or a glutamine residue (e.g. FGLQPRY) and which is targeted by MTG (i.e. a substrate for MTG), optionally it comprises a spacer moiety of Cn>20 (e.g. poly-ethylene glycol, alkyl group) and/or is conjugated via a primary amine.
- Furthermore, the organic molecule can be selected from a group consisting of: peptides comprising a lysine at any position (e.g. KNAAGGG or KDAAGGG or KAYAGGG or AKETAA) or a glutamine residue at any position (e.g. FGLQPRY, SLLQGR) and which is targeted by MTG (i.e. a substrate for MTG), and which optionally contains an enzymatically cleavable peptidic sequence (e.g. valine-citrulline (VC), KNAAGGG-VC); said lysine peptide has a size (length) of (C+N)n>20 and said glutamine peptide has a size (length) of 1<(C+N)n<200.
- Preferred embodiments for the microbeads or microbead resin can be selected from a group consisting of: glass, nickel, polyethylene, polypropylene, poly(4-methulbutene), polystyrene, polyacrylate, polyethylene terephthalate, rayon, nylon, poly(vinyl butyrate), polyvinylidene difluoride (PCDF), silicones, polyformaldehyde, cellulose, cellulose acetate, nitrocellulose, and the like. Other solid supports include gelatin, glass, sepharose macrobeads, sephadex beads or dextran microcarriers such as CYTODES® (Pharmacia, Uppsala, Sweden), polysaccharide such as agarose, alginate, carrageenan, chitin, cellulose, dextran or starch, polycaprolactone (PCL), polyacrylamide, polystyrene, polyacrolein, polydimethylsiloxane, polyvinyl alcohol, polymethylacrylate, perfluorocarbon, inorganic compounds such as silica, glass, kieselguhr, alumina, gold, iron oxide, graphene & graphene oxide or other metal oxides, or copolymers consisting of any combination of two or more naturally occurring polymers, synthetic polymers or inorganic compounds. The bead size can vary from 1 to 100 nm or from 100 to 1000 nm or from 1 μm to 10 μm or from 10 μm to 1000 μm.
- Suitable examples for the fluid can be selected from a group consisting of: water containing suitable buffer (e.g. Tris) and salt additives (e.g. NaCl), said aqueous buffer solutions also may contain glycerol and other organic solvents like ethanol, propanol, isopropanol, 1-propanol, DMSO, methanol, acetonitrile up to 60%.
- Besides first and second and higher generation dendronized polymer (de-PG2), suitable polymers can be selected from a group consisting of:
- polyethylene glycol, polypropylene glycol, polyethyleneoxide, poly(alkyloxazolines), polyvinylpyrrolidione, polylysine and polyglutamate, poly(ethyloxazoline), polymethacrylic acid and polypropacrylic acid or mixtures and dendrimeric structures thereof. Also included are polymers based on sugar residues, poly-N-isopropylacrylamide (polyNIPAM), poly(glycidyl methacrylate), polytetrafluoroethylene (PTFE) and poly(ethylene-alt-tetrafluoroethylene) (ETFE), poly(oligoethylene glycol)meth-acrylate (POEGMA), poly(2-methyl-2-oxazoline) (PMOXA), poly(vinyl alcohol) (PVA) and poly(ethylene imine) and derivatives thereof.
- In some embodiments the conjugation of the MTG and the polymer involves a linker (spacer) among the polymer and the MTG, said linker can be selected from a group consisting of:
- bifunctional linker system S-HyNic (succinimidyl-6-hydrazino-nicotinamide, S-4FB (4-formylbenzoate) or derivatives thereof, or SMCC (succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate) or derivatives thereof, homo- or heterobifunctional spacers which have a structure like Y-S-Z (Y can also be Z and vice versa), whereas Y and Z are of the following group or derivatives thereof: tetrazines, trans-cyclooctenes, azides, cyclooctenes (e.g. dibenzylcyclooctyne or bicyclononynes), n-hydroxysuccinimide, maleimide, isothiocyanate, aldehyde, epoxides, alcohols, amines, thiols, phosphonates, alkynes, potassium acyltrifluoroborates, a-ketoacid-hydroxylamines, O-acylhydroxylamines, carboxylic acids, hydrazines, imines, norborenes, nitriles and cyclopropenes, and S is a spacer entity being a polymer or derivatives thereof, e.g. oligo or poly(ethylene glycol) (PEG), dextranes, made of an alkylmoieties, amino acids or peptide derivatives
- Suitable conditions for the conjugation proceed can be achieved when the determined conditions comprise the following details: a temperature range between 0° C. and 50° C., contact time of a few seconds to 168 h (or 7 d), a flow-speed/velocity of smaller than 1 μL/min or 1 μL/min-10 ml/min in the active flow reactor column, protein concentrations of 1 μM to 1 mM with an organic molecule molar ratio to the target protein of 0.5 to 50x or 50 to 500x or 500 to 10′000x and with a MTG concentration of 0.001 mg/ml to 0.01 mg/ml or 0.01 mg/ml to 10 mg/ml per ml of resin or microbeads or of the conjugation solution, further preferably also including a conjugation efficiency to the target protein with the organic molecule of at least 30% and up to 100% conversion and a flow-pressure of 0.1 bar to 20 bar.
- In addition, the functionalized microbeads can also be placed in a spin-column suitable device, where the reaction mixture is incubated with the microbeads for a certain amount of time from 1 s to 60 s, 1 min to 60 min, 1 h to 168 h. The mixture is then removed from the microbeads again by centrifugation and taking away the supernatant or the solution is pushed through a suitable filter device during centrifugation retaining the microbeads but not the reaction desired mixture/conjugate.
- Preferred embodiments of the present invention are hereinafter described in more detail with reference to the attached drawings which depict in:
-
FIG. 1 schematically the microbial transglutaminase MTG immobilization process on de-PG2 polymer and subsequent adsorption on microbeads; -
FIGS. 2A-2D characteristics and quantification of the conjugation of the MTG on the de-PG2 polymer and MTG, MTG-polymer conjugate activity normalized to 1 μM MTG; -
FIGS. 3A-3C schematically the conjugation of functional molecules to antibody-like scaffolds like scFV and Fab-Fragment using microbead-immobilized MTG; -
FIGS. 4A-4C schematically the conjugation of functional molecules to (non-glycosylated) antibodies (N297S or N297Q mutants) using microbead-immobilized MTG; and also MTG attached to the polymer detection by the anti-MTG antibody; -
FIG. 5 Immobilized MTG enhanced selectivity in the presence of several reactive amino acids compared to when the conjugation is done in solution; -
FIG. 6 Screening of glutamine containing peptides (sequence given in table on the right) to deglycosylated IgG1 (Herceptin) using different pH conditions.Peptide 2 was found to be most potent at pH 7.6 yielding≥50% conjugation; -
FIG. 7 Structure of peptide 2 (left) and its azide-derivative (right); -
FIG. 8 Conjugation of deglycosylated IgG1 with peptide FGLQRPY (peptide 2) using solid-phase immobilized MTG; -
FIG. 9 Conjugation ofpeptide 2 to IgG1 (contains a N297S mutation) with immobilized MTG (left) and with MTG in solution (right) yielding>70% conjugation; -
FIG. 10 Conjugation of peptide 2-azide derivative to lysine 340 and lysine 288/290 of IgG1 N297S antibody with immobilized MTG (left) and with MTG in solution (right) yielding>70% conjugation; -
FIG. 11 Dual site-specific conjugation using immobilized (left) and MTG in solution (right) to IgG1 N297S antibody yielding ˜40% dual site-specifically modified IgG1. The substrates TCO-PEG3-NH2 for glutamine Q295 conjugation andpeptide 2 azide-derivative for lysine 340 (and 288/290) conjugation were used; and -
FIG. 12 SDS-PAGE coomassie and fluorescence analysis of lysine conjugated antibodies. Only heavy chains are selectively conjugated, no light chain. - Formation and Characterization of MTG-Polymer-Conjugate
- For the conjugation of N-succinimidyl-4-formylbenzamide (4FB) to the microbial transglutaminase (MTG) (
FIG. 1 ) different linker excesses were investigated aiming for one linker per MTG. The linker ratio was quantified with LC-MS and spectrophotometrically by UV-VIS and both methods were found to correlate well (FIG. 2a ). At an equal linker amount of MTG to 4FB, a conjugation ratio of approx. 0.4 was obtained which increased to ˜0.8 for an excess of 2 (FIG. 2a ). Even though a ratio of 0.8 seemed desirable we chose to use an equivalent of 1.5 4FB resulting in a linker ratio of ˜0.5 as during the course of experimenting we observed that a too high linker ratio of 0.8 resulted in an enzyme-polymer conjugate which could not be purified with ultracentrifugation due to sample precipitation. This can be attributed to the amount of>20% doubly linked MTG (MTG-(4FB)2) for 2 equivalents and which in contrast remained<10% for 1.5 equivalents (FIG. 2b ). A too high amount of MTG-(4FB)2 could lead to undesired over-crosslinking on the same or another polymer-strand, to a reduced MTG activity as well as to a decreased solubility of the enzyme-polymer conjugate. For these reasons particular emphasis was taken not to over-conjugate the MTG and chose an excess of 1.5 4FB to MTG generating>90% pure, single-linked MTG. - Polymer de-PG2500 conjugated to N-succinimidyl 6-hydrazinonicotinate (S-HyNic)-linker (
FIG. 1 ) was then incubated with MTG-4FB. Mixing of these two linked compounds led to a characteristic peak formation and absorption increase at 354 nm as followed by UV-VIS (FIG. 2c ) and which corresponded to the formation of a bis-aryl-hydrazone (BAH)-bond and the successful generation of the enzyme-polymer conjugate. - Activity of the polymer-enzyme conjugate was assayed in solution with the colorimetric hydroxylamine-amine assay and found MTG to be yet catalytically active although clearly reduced compared to native MTG (
FIG. 2d ). The decrease in activity could be explained by decreased rotational freedom and arrangement possibilities of polymer-immobilized MTG compared to the unbound, native MTG making it for the hydroxylamine more difficult to enter the enzyme's active site. Similar observations of reduced activity have been reported for proteinase K immobilized on the same polymer in solution. Even though, most importantly the MTG was yet catalytically active after immobilization. - Calculating the Amount of Adsorbed MTG-Polymer Conjugate on Microbead Glass Surfaces
- The UV-VIS quantifiable bis-aryl-hydrazone bond at 354 nm (29′000 M−cm−1) allowed to estimate the bead-immobilized MTG amount from eluted volume. After 1 h incubation, the concentration was determined to 1.6±0.15 μM in the eluted volume and given the starting concentration of 5 μM, about 70% of the conjugate has adsorbed on the beads. Since the MTG is mostly single cross-linked to the polymer, we can estimate an adsorbed mass of ˜300 ng/cm2 or ˜7.8 pmol MTG/cm2. These values agree to previously published results using proteinase K or horseradish-peroxidase immobilized on denpol-polymers and other enzymes, covalently immobilized on silica-polymer-surfaces.
- Microbead Immobilized-MTG for the Site-Specific Conjugation of Functional Molecules to Proteins
- For the stable immobilization of the MTG-polymer conjugate glass microbeads were chosen to be used due to the strong affinity of the positively charged denpol-amines to negatively charged glass surfaces and since beads can easily be assembled into a flow-based microreactor. Such a set-up enables for a repeated sample bead-overflowing in a well-controllable manner and hence can be used to drive the reaction towards completion. Furthermore, the microbeads can simply be washed after the conjugation process recovering the immobilized MTG for the next round of conjugation.
- Therapeutic relevant proteins of smaller antibody-like scaffolds including scFV, nanobodies or Fab-fragments have been of considerable interest due to their increased tumor penetration capability, their facile production and more rapid clearance compared to larger antibodies. In a first attempt to functionalize proteins, it was thus aimed to conjugate a Fab-fragment and a scFV both of which were previously shown to be efficiently conjugated by MTG in solution through the glutamine 2 (‘Q2’) in their C-terminal myc-tag using biotin-cadaverine as the amine, an ideal substrate for further downstream applications including immobilization on streptavidin coated surfaces. Although flexible loops and terminal tags on proteins containing a glutamine are known to be preferentially targeted by MTG the globular structure and the presence of an accessible terminal tag allowed for conjugation of the surface-immobilized MTG and is less challenging to enter the enzyme's active site compared to a loop structure like the glutamine 295 on bulky antibodies. One thus mixed biotin-cadaverine with c-terminal myc-tagged Fab-fragment and scFV and flowed the solutions over microbead immobilized MTG in the microreactor (
FIGS. 1 and 3 a). The solution was pumped for 30 min over the microreactor and subjected to LC-MS analysis. Complete conversion of≥95% to the desired biotin-conjugated Fab-fragment was found with no unconjugated material detectable (FIG. 3b ). Also c-myc-tagged scFV was efficiently conjugated to yield≥95% of the desired conjugate under the same conditions within solely 30 min (FIG. 3b ). - Dansylcadaverine, a fluorescent amine donor for MTG, was also conjugated at an excess of just 8 equimolar to Fab and scFV (
FIG. 3a ) which resulted in≥95% dansyl-labeled Fab-Fragment and ≥90% scFV within 30 min (FIG. 3b ). - In some cases direct conjugation of bulky primary amine containing substrates to MTG-reactive glutamines occasionally results in incomplete product conversion with residual unconjugated material. This particularly occurs for those substrates containing highly hydrophilic groups like carboxy-groups on metal chelators. Using a two-step approach where first a “click-able” moiety is installed on the protein followed by the click-conjugation of the desired molecule, this problem can be circumvented generating quantitative conjugation. It was therefore explored whether conjugation could be done with an amine-PEG3-azide, suitable for SPAAC (strain-promoted alkyne-azide cycloaddition) click-chemistry (
FIG. 3c ) to myc-tagged scFV. Myc-tagged scFV was flowed over the column and after 30 min, sample was withdrawn and subjected to LC-MS analysis already yielded desired scFV-N3 conversion to 82% (FIG. 3c ). Sustained bead-overflowing for 90 min resulted in 97% conversion, while no unconjugated material was detectable anymore after continuous overnight flowing (14 h) (FIG. 3c ). These results clearly demonstrate that microbead-immobilized-MTG was able to quantitatively conjugate various substrates to myc-tagged proteins within less than 90 min, even at low reagent excess. - Based on these results it was explored whether full antibodies could also be conjugated by bead-immobilized MTG. Previously, one pinpointed glutamine 295 (Q295) of deglycosylated antibodies, located on the flexible C′E loop of the Fc-domain, as the sole MTG target-site within an antibody backbone, therefore generating a defined antibody-conjugate with two or four attachment sites, if a N297Q point mutation is introduced ablating the glycosylation site. Antibody conjugation on a surface might be more challenging than in solution due to the antibody's bulkiness restricting its orientation possibilities and thus making the MTG-access to Q295 and Q297, resp. to the loop likely more difficult.
- Immobilized MTG was therefore subjected to an IgG1 antibody containing a N297S point mutation to obviate deglycosylation and biotin-cadaverine (
FIG. 4a ). After 30 min, LC-MS analysis of reduced antibody already showed 37% heavy chain conversion and 72% after 1 h at room temperature, increasing to 95% during overnight incubation (FIG. 4a ). Site-specifically modified antibodies with high drug-to-antibody-ratio (DAR) of 4-6 are considered to effectively deliver the conjugated drugs to the tumor target site compared to conventionally, non-specifically conjugated antibodies having the same drug load making such ADCs very attractive as improved cancer therapeutics. It was therefore investigated whether the immobilized MTG would sustain its capability to conjugate two SPAAC amenable bifunctional linkers in very close proximity to the N297Q antibody (FIG. 4b ). It was found that the bead-immobilized MTG could indeed quantitatively and efficiently conjugate both linkers yielding a N297Q antibody with ratio of 4 linkers per antibody (FIG. 4b ). - These studies clearly revealed that the specific and efficient conjugation capability of the MTG was sustained upon immobilization and even enabled to tune residue specificity of proteins.
- Stability Investigation of MTG-Polymer Conjugate and MTG Activity on Microbead
- The polycationic nature of the denpol-polymer was previously shown to provide a stable surface-anchoring for several weeks on anionic glass surfaces. Since a solid enzyme immobilization is important for downstream applications particularly for prospective therapeutic proteins, one addressed enzyme-leaking using slot-blot assay and anti-MTG antibody. One chose slot-blot as it allows application of large sample volumes and due to its sensitivity. MTG-polymer conjugate as a positive control showed a strong signal (
FIG. 4c , lane 1 I), also unconjugated MTG could be detected (lane 1, ii) while HyNic-polymer did not produce a signal (lane 1 iii) demonstrating that the antibody specifically recognized the MTG, also when conjugated to the polymer. After continuous operation of 14 h, MTG remained firmly attached (lane 2, i and ii) and also after 40 h of operation performing several conjugations the MTG remained firmly attached to the polymer with no enzyme detectable (lane 2, iii). Under the latter conditions, immobilized MTG was yet able to conjugate BC to>90% to N297S IgG1 after 3 h. From these data it was concluded that the MTG not only remained tightly attached to the glass microbead but also was active for an extended time period and several rounds of conjugation, resp. and thus is a very promising tool for the conjugation of proteins with similar size range than MTG. - Increase of Residue Selectivity in the Presence of Multiple MTG Reactive Amino Acids of Immobilized MTG
- It has been reported that immobilized enzymes show increased selectivity towards substrates and thus, it was supposed that this could also apply to immobilized MTG. Conjugation in solution of ZQG-Tamra-cadaverine (ZQG-TC) to avidin (serving as a model protein), which possesses several reactive lysine residues, using MTG showed two major peaks in the deconvoluted LC-MS spectrum. These peaks correspond to avidin with one ZQG-TC and avidin with two conjugated ZQG-TC as well as some unmodified avidin (
FIG. 5 , left panel). Doing the same experiment but using immobilized MTG it was surprisingly found that MTG almost exclusively targeted one lysine residue of avidin with only limited conjugation to the second residue (FIG. 5 , right panel), perhaps because of decreased rotational MTG-flexibility. These data show that immobilized MTG indeed can be used to tune residue selectivity which is inaccessible with solution-phase conjugation where two residues were predominantly conjugated. - Site-Specific Conjugation of Small Glutamine Containing Peptides to Lysine Residues of de- and aglycosylated IgG1
- Although MTG-mediated functionalization of antibodies via lysine side chains using ZQG-derivatives has been reported, the conjugation yield was unsatisfactory (i.e. <20%) and no modified lysine sites were reported. Thus, further investigations have been aimed to target lysine residues of aglycosylated and deglycosylated IgG1s in solution and with immobilized MTG. It was reasoned that different glutamine peptides might be more efficiently conjugated towards lysine residues on IgG1 than the commonly applied ZQG or derivatives thereof. Thus, one first screened a small library of glutamine containing peptides with a reported high MTG activity in solution under different pH conditions which we subsequently wanted to apply to immobilized MTG. Indeed, once was able to identify sequences with favorable conjugation ratios to deglycosylated IgG1 after 16 h incubation at room temperature, showing higher reactivity than ZQG (
FIG. 6 ) using LC-MS for analysis. Particularly the peptide sequence NH2-FGLQRPY-COOH showed an almost two-fold higher conjugation efficiency of almost 50% over ZQG in solution at pH 7.6 to deglycosylated IgG1 (FIG. 6 ). Subjecting deglycosylated IgG1 and peptide FGLQRPY (peptide 2,FIG. 7 left for peptide structure) to immobilized MTG overnight at room temperature, a conjugation of 30% was found (FIG. 8 ). Strikingly, using the IgG1 aglycosylated N297S mutant and FGLQRPY the conjugation ratio increased to 71% with immobilized and MTG in solution (FIG. 9 left and right, resp.). The same result was obtained using FGLQRPY azide-derivative (FIG. 7 right for peptide structure) with immobilized MTG and MTG in solution (FIG. 10 left and right, resp.) using LC-MS for analysis. One predominantly found a single modified species and only a minor second conjugation using LC-MS for analysis, both exclusively located on the heavy chain. Peptide mapping confirmed two modification sites at Lys288 or Lys 290 and at Lys340. - Site-Specific Dual Conjugation with Immobilized and MTG in Solution to aglycosylated IgG1 (N297S Mutant)
- Having established glutamine and lysine conjugation with immobilized and MTG in solution it was reasoned whether site-specific dual modification would be feasible with immobilized and MTG in solution by modifying Q295 and K340, K288/K290 of the N297S IgG1. Such dual-modified antibodies with e.g. two imaging probes would be very suitable for e.g. non-invasive and/or intra/post-operative tissue imaging. Alternatively, two different toxic payloads could be attached that show synergistic effects. Q295 was first modified with NH2-PEG3-TCO to≥95% followed by modification with peptide-2 azide derivative resulting in a slightly lower yield of 38% dual site-specifically modified IgG1 (
FIG. 11 , left) Dual site-specific conjugation with MTG in solution yielded similar results (FIG. 11 , right). SDS-PAGE confirmed heavy-chain specific conjugation to lysine residues, also for the dual-conjugated antibody confirming LC-MS results (FIG. 12 ). - Conjugation of Functional Lysine Peptides to deglycosylated Antibodies
- It was also investigated if peptides containing a lysine residue could also be used to site-specifically modify deglycosylated antibodies at the glutamine 295 position with MTG in solution, this so far has not been described in the literature. Equipping such peptides with a functional group such as a N3-group (KAYA-GGG-N3) or metal chelators (e.g. NODAGA) would in the first case allow to subsequently attach another moiety by e.g. SPAAC-click chemistry at low molar equivalents. In the second case a functional moiety could directly be conjugated, a second step is thus not necessary which facilitates further downstream processing. In addition, by the incorporation of hydrophilic amino acids in the peptide the solubility of the functional moiety (“the payload”) could be increased which is very beneficial for hydrophobic payloads. In the present work, it has been shown that KAYA-GGG-N3 can be conjugated with high efficiency (>95%) as well as KNAA-GK-PEG3-NODAGA and KAYA-GK-PEG3-NODAGA to deglycosylated antibody.
Claims (27)
1. A method for conjugating a peptide linker comprising a lysine and/or a glutamine residue to an antibody, or an antigen-binding fragment thereof, by means of a microbial transglutaminase (MTG) the method comprising:
a) mixing the antibody, or the antigen-binding fragment thereof, the peptide linker and the MTG within a fluid under determined conditions, thereby conjugating the peptide linker to the antibody, or the antigen-binding fragment thereof, under the catalyzing effect of the MTG, wherein the peptide linker is mixed with the antibody, or the antigen-binding fragment thereof, at a 0.5x to 50x molar ratio; and
b) extracting the conjugate obtained in step (a) from the fluid.
2. The method according to claim 1 , wherein the MTG concentration in the fluid is 0.01 mg/mL to 10 mg/mL.
3. The method according to claim 1 , wherein a conjugation efficiency to the antibody, or the antigen-binding fragment thereof, of at least 30% is achieved.
4. The method according to claim 1 , wherein the peptide linker is a linker comprising a lysine residue.
5. The method according to claim 1 , wherein the fluid is an aqueous buffer solution.
6. The method according to claim 5 , wherein the aqueous buffer solution comprises Tris and NaCl.
7. The method according to claim 1 , wherein the antibody, or the antigen-binding fragment thereof, the peptide linker and the MTG are mixed at a pH of 7.6.
8. The method according to claim 1 , wherein the antibody is an antibody of IgG, IgM, IgA or IgE format, or a fragment thereof.
9. The method according to claim 1 , wherein the antigen-binding fragment is a Fab, a Fab′, a F(ab′)2, a F(ab′)3, a Dab, an Fv fragment, a single chain Fv (scFv) fragment or a scFv-Fc (scFv)2.
10. The method according to claim 1 , wherein the MTG modifies either one or more reactive glutamine residue or one or more reactive lysine residue on the antibody, or the antigen-binding fragment thereof, with the peptide linker; wherein the one or more reactive glutamine or lysine residue
a) is an endogenous glutamine or lysine residue;
b) has been artificially introduced into the antibody, or the antigen-binding fragment thereof, by genetic means; or
c) a combination of (a) or (b).
11. The method according to claim 1 , wherein the peptide linker further comprises a fluorescent dye/label, a cell-cytotoxic or influencing moiety, a metal-chelator a functional peptide, a chemical moiety and/or a spacer moiety with Cn, >20.
12. The method according to claim 1 , wherein the peptide linker further comprises an enzymatically cleavable peptide sequence.
13. The method according to claim 1 , wherein the peptide linker comprises the sequence KNAA, KAYA, KNAAGGG KDAAGGG, KAYAGGG, AKETAA, FGLQPRY or SLLQGR.
14. The method according to claim 1 wherein the peptide linker further comprises a self-immolative group.
15. The method according to claim 14 , wherein the self-immolative group is p-aminobenzyloxycarbonyl (PAB).
16. The method according to claim 1 , wherein the antibody is a monoclonal antibody, a chimeric antibody, a humanized antibody, a human antibody or a bispecific antibody, and/or wherein the antibody is deglycosylated or non-glycosylated containing a mutation at residue N297 in the EU numbering scheme.
17. The method according to claim 11 , wherein the cell-cytotoxic or influencing moiety is a toxin or an immune cell immunomodulatory/stimulating compound; and/or
wherein the metal-chelator is suitable for SPECT/PET or MRI; and/or
wherein the chemical moiety comprises a reactive group suitable for a click reaction; and/or
wherein the spacer moiety comprises an alkyl or heteroalkyl chain, or a derivative thereof, or a polyethylene glycol moiety.
18. The method according to claim 17 , wherein the toxin is MMAE; and/or
wherein the reactive group suitable for a click reaction comprises an azide moiety, a cyclooctyne moiety, a tertrazine moiety, a trans-cyclooctene moiety, or a derivative thereof.
19. The method according to claim 1 , wherein the fluid comprises up to 60% of glycerol and/or an organic solvent.
20. The method according to claim 1 , wherein the lysine peptide has a size of (C+N)n>20 and said glutamine peptide has a size of 1<(C+N)n<200.
21. The method according to claim 1 , wherein the MTG is conjugated to a polymer.
22. The method according to claim 21 , wherein the MTG polymer conjugate is immobilized on a microbead via a covalent and/or ionic bond.
23. The method according to claim 22 , wherein the microbeads are selected from the group consisting of: glass, nickel, polyethylene, polypropylene, poly(4-methulbutene), polystyrene, polyacrylate, polyethylene terephthalate, rayon, nylon, poly(vinyl butyrate), polyvinylidene difluoride (PCDF), silicones, polyformaldehyde, cellulose, cellulose acetate, nitrocellulose, gelatin, polysaccharides, polycaprolactone (PCL), polyacrylamide, polyacrolein, polydimethylsiloxane, polyvinyl alcohol, polymethylacrylate, perfluorocarbon, inorganic compounds, or copolymers consisting of any combination of two or more naturally occurring polymers, synthetic polymers or inorganic compounds and/or wherein the size of the microbead varies from 1 nm to 1000 μm.
24. The method according to claim 23 , wherein the polysaccharide is agarose, alginate, carrageenan, chitin, dextran or starch; and/or wherein the inorganic compound is silica, glass, kieselguhr, alumina, gold, iron oxide, graphene, graphene dioxide or another metal oxide.
25. The method according to claim 21 , wherein the polymer is selected from the group consisting of: polyethylene glycol, polypropylene glycol, polyethyleneoxide, poly(alkyloxazolines), polyvinylpyrrolidone, polylysine and polyglutamate, poly(ethyloxazoline), polymethacrylic acid and polypropacrylic acid or mixtures and dendrimeric structures thereof; also included are polymers based on sugar residues, poly-N-isopropylacrylamide (polyNIPAM), poly(glycidyl methacrylate), polytetrafluoroethylene (PTFE) and poly(ethylene-alt-tetrafluoroethylene) (ETFE), poly(oligoethylene glycol) meth-acrylate (POEGMA), poly(2-methyl-2-oxazoline) (PMOXA), poly(vinyl alcohol) (PVA) and poly(ethylene imine) and derivatives thereof and/or wherein the polymer is a second generation dendronized polymer (dePG2).
26. The method according to claim 21 wherein the MTG polymer conjugate is involving a linker (spacer) between the polymer and the MTG, said linker is a bifunctional linker system S-HyNic (succinimidyl-6-hydrazino-nicotinamide, S-4FB (4-formylbenzoate) or derivatives thereof, or SMCC (succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate) or derivatives thereof, homo- or heterobifunctional spacers which have a structure like Y-S-Z (Y can also be Z and vice versa), whereas Y and Z are of the following group or derivatives thereof: tetrazines, trans-cyclooctenes, azides, cyclooctenes (e.g. dibenzylcyclooctyne or bicyclononynes), n-hydroxysuccinimide, maleimide, isothiocyanate, aldehyde, epoxides, alcohols, amines, thiols, phosphonates, alkynes, potassium acyltrifluoroborates, a-ketoacid-hydroxylamines, O-acylhydroxylamines, carboxylic acids, hydrazines, imines, norborenes, nitriles and cyclopropenes, and S is a spacer entity being a polymer or derivatives thereof, e.g. oligo or poly(ethylene glycol) (PEG), dextranes, made of an alkylmoieties, amino acids or peptide derivatives.
27. The method according to claim 21 , wherein the MTG polymer conjugate is retained in an active flow reactor.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/704,960 US20220333093A1 (en) | 2016-07-20 | 2022-03-25 | Site-specific conjugation to antibody lysine residues with solid-phase immobilized microbial transglutaminase mtg and mtg in solution |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16180382.0A EP3272864A1 (en) | 2016-07-20 | 2016-07-20 | Solid-phase immobilization of microbial transglutaminase mtg on microbeads for protein conjugation |
EP16180382.0 | 2016-07-20 | ||
PCT/EP2017/067403 WO2018015213A1 (en) | 2016-07-20 | 2017-07-11 | Site-specific conjugation to antibody lysine residues with solid-phase immobilized microbial transglutaminase mtg and mtg in solution |
US201916319502A | 2019-01-22 | 2019-01-22 | |
US17/704,960 US20220333093A1 (en) | 2016-07-20 | 2022-03-25 | Site-specific conjugation to antibody lysine residues with solid-phase immobilized microbial transglutaminase mtg and mtg in solution |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/319,502 Continuation US11396649B2 (en) | 2016-07-20 | 2017-07-11 | Site-specific conjugation to antibody lysine residues with solid-phase immobilized microbial transglutaminase MTG and MTG in solution |
PCT/EP2017/067403 Continuation WO2018015213A1 (en) | 2016-07-20 | 2017-07-11 | Site-specific conjugation to antibody lysine residues with solid-phase immobilized microbial transglutaminase mtg and mtg in solution |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220333093A1 true US20220333093A1 (en) | 2022-10-20 |
Family
ID=56561217
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/319,502 Active 2038-12-15 US11396649B2 (en) | 2016-07-20 | 2017-07-11 | Site-specific conjugation to antibody lysine residues with solid-phase immobilized microbial transglutaminase MTG and MTG in solution |
US17/704,960 Abandoned US20220333093A1 (en) | 2016-07-20 | 2022-03-25 | Site-specific conjugation to antibody lysine residues with solid-phase immobilized microbial transglutaminase mtg and mtg in solution |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/319,502 Active 2038-12-15 US11396649B2 (en) | 2016-07-20 | 2017-07-11 | Site-specific conjugation to antibody lysine residues with solid-phase immobilized microbial transglutaminase MTG and MTG in solution |
Country Status (6)
Country | Link |
---|---|
US (2) | US11396649B2 (en) |
EP (2) | EP3272864A1 (en) |
JP (3) | JP7044755B2 (en) |
KR (1) | KR102138195B1 (en) |
CN (1) | CN109475641A (en) |
WO (1) | WO2018015213A1 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108341404B (en) * | 2018-04-11 | 2021-03-30 | 福州大学 | Three-dimensional porous boron-carbon-nitrogen material and preparation method and application thereof |
JP2022522502A (en) * | 2019-03-06 | 2022-04-19 | キュリー カンパニー インコーポレイテッド | Preservative composition and its usage |
CN109994163A (en) * | 2019-03-22 | 2019-07-09 | 陕西省生物农业研究所 | A kind of simulation natural polymers design a model |
PL3865155T3 (en) * | 2020-02-13 | 2023-01-30 | Orano Med | Process for site-specific modification of an antibody |
CN111662410B (en) * | 2020-07-06 | 2021-03-30 | 华南农业大学 | Sandwich-structure molecularly imprinted SERS substrate and preparation method and application thereof |
WO2022170676A1 (en) * | 2021-02-09 | 2022-08-18 | Genequantum Healthcare (Suzhou) Co., Ltd. | Conjugation device and method for producing conjugates |
EP4153241A4 (en) | 2021-02-09 | 2023-12-06 | Genequantum Healthcare (Suzhou) Co., Ltd. | Conjugation device and method for producing conjugates |
CN113264868B (en) * | 2021-05-31 | 2022-12-02 | 山东华素制药有限公司 | Improved synthesis method of 1-benzyl-3-piperidinol |
AU2022306788A1 (en) | 2021-07-09 | 2024-01-04 | Bright Peak Therapeutics Ag | Conjugates of checkpoint inhibitors with il-2, and uses thereof |
KR20240041379A (en) | 2021-07-09 | 2024-03-29 | 브라이트 피크 테라퓨틱스 아게 | Checkpoint inhibitors conjugated to IL-2 and uses thereof |
WO2023281481A1 (en) | 2021-07-09 | 2023-01-12 | Bright Peak Therapeutics | Antibody conjugates and manufacture thereof |
EP4366779A1 (en) | 2021-07-09 | 2024-05-15 | Bright Peak Therapeutics AG | Modified tnf-antibodies and uses thereof |
US20230201365A1 (en) | 2021-07-09 | 2023-06-29 | Bright Peak Therapeutics Ag | Modified cd20 antibodies and uses thereof |
CN114163549B (en) * | 2022-01-06 | 2022-10-04 | 苏州乙水茉生物科技有限公司 | Chitosan oligosaccharide and bivalent plant vaccine covalent conjugate and preparation method and application thereof |
WO2023161854A1 (en) | 2022-02-23 | 2023-08-31 | Bright Peak Therapeutics Ag | Immune antigen specific il-18 immunocytokines and uses thereof |
CN117230054B (en) * | 2023-11-16 | 2024-03-19 | 广东惠尔泰生物科技有限公司 | Preparation method of immobilized lipase and method for preparing UPU type glyceride by using immobilized lipase |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005507650A (en) | 2001-08-01 | 2005-03-24 | セロミックス インコーポレイテッド | Assays for novel fusion proteins and molecular binding |
GB0301117D0 (en) * | 2003-01-17 | 2003-02-19 | Danisco | Method |
US7955814B2 (en) | 2003-01-17 | 2011-06-07 | Danisco A/S | Method |
EP2278015B1 (en) * | 2003-01-17 | 2014-08-13 | DuPont Nutrition Biosciences ApS | Method of producing a carbohydrate ester |
JP5796860B2 (en) * | 2009-12-22 | 2015-10-21 | ライフボンド リミテッドLifebond Ltd | Modification of enzymatic crosslinkers to adjust the properties of the cross-linked matrix |
EP2550529B1 (en) | 2010-03-23 | 2021-11-17 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
CA2930801C (en) | 2010-11-05 | 2019-05-28 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
EP2771349B1 (en) | 2011-09-16 | 2020-02-26 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
WO2013049830A2 (en) | 2011-09-30 | 2013-04-04 | The Washington University | Tip-1 and grp-78 binding peptides and method of identifying peptide receptors |
EP2777714A1 (en) | 2013-03-15 | 2014-09-17 | NBE-Therapeutics LLC | Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme |
EP2968582B1 (en) | 2013-03-15 | 2020-07-01 | Innate Pharma | Solid phase tgase-mediated conjugation of antibodies |
WO2014202775A1 (en) | 2013-06-21 | 2014-12-24 | Innate Pharma | Enzymatic conjugation of polypeptides |
BR112016024370A2 (en) | 2014-04-25 | 2017-10-10 | Pfizer | high drug loading antibody-drug conjugates |
EP3154574B1 (en) | 2014-06-12 | 2022-05-11 | CSPC Megalith Biopharmaceutical Co., Ltd. | Homogenous antibody drug conjugates via enzymatic methods |
CA2971402C (en) | 2014-12-19 | 2023-08-01 | F. Hoffmann-La Roche Ag | Microbial transglutaminases, substrates therefor and methods for the use thereof |
WO2016128410A1 (en) | 2015-02-09 | 2016-08-18 | Nbe Therapeutics Ag | Maytansine-drug conjugates of her- 2 specific binding proteins generated by site specific sortase-enzyme mediated conjugation |
CN107406496A (en) | 2015-03-10 | 2017-11-28 | 百时美施贵宝公司 | The antibody and conjugate prepared therefrom that can be conjugated by transglutaminase |
US10973923B2 (en) | 2015-06-23 | 2021-04-13 | Bayer Pharma Aktiengesellschaft | Site specific homogeneous with KSP inhibitors |
MX2020001212A (en) | 2017-08-07 | 2020-03-20 | Nbe Therapeutics Ag | Anthracycline-based antibody drug conjugates having high in vivo tolerability. |
-
2016
- 2016-07-20 EP EP16180382.0A patent/EP3272864A1/en not_active Withdrawn
-
2017
- 2017-07-11 US US16/319,502 patent/US11396649B2/en active Active
- 2017-07-11 WO PCT/EP2017/067403 patent/WO2018015213A1/en unknown
- 2017-07-11 EP EP17742684.8A patent/EP3487540A1/en active Pending
- 2017-07-11 JP JP2019502618A patent/JP7044755B2/en active Active
- 2017-07-11 CN CN201780045202.XA patent/CN109475641A/en active Pending
- 2017-07-11 KR KR1020197004547A patent/KR102138195B1/en active IP Right Grant
-
2022
- 2022-01-18 JP JP2022005624A patent/JP7343628B2/en active Active
- 2022-03-25 US US17/704,960 patent/US20220333093A1/en not_active Abandoned
-
2023
- 2023-08-31 JP JP2023141432A patent/JP2023164911A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR102138195B1 (en) | 2020-07-28 |
US11396649B2 (en) | 2022-07-26 |
EP3487540A1 (en) | 2019-05-29 |
CN109475641A (en) | 2019-03-15 |
JP7343628B2 (en) | 2023-09-12 |
EP3272864A1 (en) | 2018-01-24 |
WO2018015213A1 (en) | 2018-01-25 |
JP2022058642A (en) | 2022-04-12 |
KR20190029684A (en) | 2019-03-20 |
JP2023164911A (en) | 2023-11-14 |
US20190194641A1 (en) | 2019-06-27 |
JP7044755B2 (en) | 2022-03-30 |
JP2019531050A (en) | 2019-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220333093A1 (en) | Site-specific conjugation to antibody lysine residues with solid-phase immobilized microbial transglutaminase mtg and mtg in solution | |
Gao et al. | Oriented immobilization of antibodies onto sensing platforms-A critical review | |
Yamada et al. | Recent Chemical Approaches for Site‐Specific Conjugation of Native Antibodies: Technologies toward Next‐Generation Antibody–Drug Conjugates | |
Zhang et al. | Recent progress in enzymatic protein labelling techniques and their applications | |
Shen et al. | Site-selective orientated immobilization of antibodies and conjugates for immunodiagnostics development | |
Samanta et al. | Immobilization of bio-macromolecules on self-assembled monolayers: methods and sensor applications | |
Dennler et al. | Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody–drug conjugates | |
Montenegro et al. | Controlled antibody/(bio-) conjugation of inorganic nanoparticles for targeted delivery | |
Kudirka et al. | Site-specific tandem knoevenagel condensation–michael addition to generate antibody–drug conjugates | |
Palomo | Diels–Alder cycloaddition in protein chemistry | |
JP5205465B2 (en) | Method for producing antibody monolayer with controlled orientation using peptide hybrid | |
KR20230118570A (en) | Affinity reagents with enhanced binding and detection properties | |
Doti et al. | A recent update on the use of microbial transglutaminase for the generation of biotherapeutics | |
Alves et al. | Conjugation of a reactive thiol at the nucleotide binding site for site-specific antibody functionalization | |
Brasino et al. | Creating highly amplified enzyme-linked immunosorbent assay signals from genetically engineered bacteriophage | |
Grunewald et al. | Optimization of an enzymatic antibody–drug conjugation approach based on coenzyme A analogs | |
Weerasuriya et al. | Magnetic nanoparticles with surface nanopockets for highly selective antibody isolation | |
Le et al. | Antibody functionalization with a dual reactive hydrazide/click crosslinker | |
US5532170A (en) | Processing analytical reagents | |
Yu et al. | Site-specific albumin-selective ligation to human serum albumin under physiological conditions | |
Watanabe et al. | Scale-up synthesis of site-specific antibody–drug conjugates using AJICAP second-generation technology | |
Fujii et al. | Bispecific Antibodies Produced via Chemical Site-Specific Conjugation Technology: AJICAP Second-Generation | |
AU746325B2 (en) | Methods for covalent immobilisation of biomolecules to a carrier by means of a His-tag | |
Yamazaki et al. | Lipoic Acid Ligase A‐Mediated Ligation: Mechanism, Applications, and Emerging Innovations in Bioconjugation | |
Dixit et al. | Antibody immobilization chemistries for nanosurfaces |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |